Ramucirumab+docetaxel post immune checkpoint inhibitors and platinum-based chemotherapy in advanced or metastatic non-small cell lung cancer: Learnings from the TREAT-LUNG Observational Study

Ramucirumab+docetaxel post immune checkpoint inhibitors and platinum-based chemotherapy in advanced or metastatic non-small cell lung cancer: Learnings from the TREAT-LUNG Observational Study

Abstract OBJECTIVES: Adding ramucirumab to docetaxel after failure of chemo improves response rates and survival in aNSCLC. TREAT-LUNG aimed to characterize real-world use of ramucirumab+docetaxel or docetaxel, following ICIs and chemo for aNSCLC. METHODS:...
Ramucirumab+docetaxel post immune checkpoint inhibitors and platinum-based chemotherapy in advanced or metastatic non-small cell lung cancer: Learnings from the TREAT-LUNG Observational Study

Evaluation of health care resource utilization and costs among bio-experienced Crohn’s disease patients treated with biologics with two years of follow-up

Abstract Objective: This study examined Crohn’s Disease (CD)-related health care resource utilization (HCRU) and costs among bio-experienced CD patients treated with biologics over a 2-year follow-up. Methods: This descriptive study used claims data pooled from Optum...
Ramucirumab+docetaxel post immune checkpoint inhibitors and platinum-based chemotherapy in advanced or metastatic non-small cell lung cancer: Learnings from the TREAT-LUNG Observational Study

Evaluation of health care resource utilization and costs among bio naïve Crohn’s disease patients initiating biologics with two years of follow-up

Abstract Objective: This study examined Crohn’s Disease (CD)-related health care resource utilization (HCRU) and costs among bio-naïve CD patients initiating biologics over a 2-year follow-up period. Methods: This descriptive study used claims data pooled from Optum...